α-Santalol/Sandalwood oil / VEGFR2 Cancer Research Results

SAO, α-Santalol/Sandalwood oil: Click to Expand ⟱
Features:

α-Santalol / Sandalwood oil — α-Santalol is a lipophilic sesquiterpene alcohol and major bioactive constituent of East Indian sandalwood oil from Santalum album. It is best classified as a natural-product small molecule / essential-oil sesquiterpenoid, with sandalwood oil functioning as a botanical mixture source rather than a single-compound drug. Standard abbreviations include α-SAN, alpha-santalol, and SAO or EISO for sandalwood album / East Indian sandalwood oil. The oncology evidence is primarily preclinical, strongest for skin, prostate, breast, and oral cancer models, with no established oncology indication.

Primary mechanisms (ranked):

  1. Induction of intrinsic and extrinsic apoptosis through caspase activation, PARP cleavage, mitochondrial involvement, and increased apoptotic signaling.
  2. Cell-cycle blockade, especially G2/M arrest, with reported tubulin interaction and mitotic disruption in oral cancer models.
  3. Suppression of AKT–survivin / IAP survival signaling, including reduced p-AKT, survivin, XIAP, PCNA, cyclin D, and CDC2 in prostate cancer models.
  4. Anti-migration and anti-invasive signaling through Wnt/β-catenin inhibition in breast cancer models.
  5. Anti-angiogenic signaling through VEGFR2–AKT/mTOR/p70S6K pathway suppression in prostate tumor models.
  6. Autophagy modulation, including AKT–mTOR-linked autophagy in prostate cancer and autophagy/cell death effects for whole sandalwood oil in proliferating keratinocytes.
  7. Skin chemopreventive modulation of UVB/chemical carcinogenesis pathways, including p53/caspase-associated apoptosis and inflammatory stress-response modulation.

Bioavailability / PK relevance: α-Santalol is a small, highly lipophilic sesquiterpene alcohol, so topical and transdermal exposure is plausible, but formal human systemic PK data are limited. Oral/transdermal use should be treated as formulation- and dose-dependent, and essential-oil exposure is not equivalent to purified α-santalol exposure.

In-vitro vs systemic exposure relevance: Most anticancer cell-culture studies use micromolar α-santalol concentrations, commonly around 20–75 μM depending on model and endpoint. These levels should be considered potentially above reliably documented human systemic exposure from sandalwood oil use, so in-vitro anticancer potency should not be interpreted as clinically achievable without dedicated PK/formulation data.

Clinical evidence status: Preclinical for cancer prevention/therapy. Small human and dermatology-oriented evidence exists for sandalwood album oil in non-oncology skin conditions, and one clinical-trial context appears related to oral mucositis/supportive care rather than anticancer efficacy. No approved oncology indication and no high-quality human RCT evidence for cancer treatment were identified.

α-Santalol and Sandalwood Oil Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Caspase apoptosis ↑ caspase-3, ↑ caspase-8, ↑ caspase-9, ↑ PARP cleavage, ↓ viability ↔ to modest toxicity at comparable experimental windows (model-dependent) R/G Pro-apoptotic anticancer effect Core mechanism across prostate, breast, and skin cancer models; includes intrinsic and extrinsic apoptotic signaling.
2 Mitochondria / MPTP ↑ mitochondrial apoptotic signaling, ↓ mitochondrial membrane integrity (model-dependent) ↔ uncertain R/G Amplifies apoptosis Mitochondrial involvement is supported mainly through caspase-9 and apoptotic readouts; direct MPTP evidence is not as strong as apoptosis evidence.
3 Cell cycle and tubulin ↑ G2/M arrest, ↓ tubulin polymerization, ↑ mitotic arrest ↔ uncertain G Anti-proliferative cytostasis and cytotoxicity Strong mechanistic relevance for oral cancer and skin/breast cancer models; tubulin interaction supports antimitotic classification.
4 AKT / survivin / IAP ↓ p-AKT, ↓ survivin, ↓ XIAP, ↓ PCNA, ↓ cyclin D, ↓ CDC2 ↔ uncertain G Reduces survival signaling and proliferation Important prostate-cancer axis; PI3K/AKT inhibition can enhance α-santalol-induced apoptosis.
5 Wnt / β-catenin migration ↓ β-catenin-linked migration and motility ↔ uncertain G Anti-migration effect Best supported in cultured breast cancer cells; therapeutic relevance remains preclinical.
6 VEGFR2 angiogenesis ↓ VEGFR2 signaling, ↓ AKT/mTOR/p70S6K, ↓ tumor angiogenesis ↔ uncertain G Anti-angiogenic effect Relevant to prostate tumor xenograft-type evidence; not yet clinically validated.
7 Autophagy / AKT-mTOR ↑ autophagy (context-dependent), ↓ AKT-mTOR signaling ↑ autophagy/cell death in proliferating keratinocytes with whole oil (context-dependent) G Context-dependent stress adaptation or cell death Autophagy may be protective in some prostate cancer contexts; combination strategies would need caution.
8 ROS / oxidative stress ↔ limited direct cancer-specific evidence for α-santalol as a primary ROS driver ↔ antioxidant effects reported in non-cancer models R/G Secondary or context-dependent redox modulation ROS is not a core anticancer mechanism unless a specific model/source directly shows ROS-dependent killing.
9 NRF2 ↔ insufficient direct α-santalol cancer evidence ↔ uncertain G Not a primary assigned mechanism
10 Glycolysis / HIF-1α ↔ insufficient direct evidence ↔ insufficient direct evidence G No clear primary modulation
11 Radiosensitization or chemosensitization ↔ limited direct evidence; possible apoptosis-combination rationale only ↔ uncertain G Unproven adjunct effect
12 Clinical Translation Constraint In-vitro potency may require exposure above documented human systemic levels Topical irritation or sensitization possible; systemic safety data limited G Limits clinical interpretation Major constraints are formulation, bioavailability, mixture variability, topical safety, and lack of oncology trials.

P: 0–30 min R: 30 min–3 hr G: >3 hr
VEGFR2, Vascular Endothelial Growth Factor Receptor 2: Click to Expand ⟱
Source:
Type: receptor tyrosine kinase
VEGFR2 is a receptor tyrosine kinase that plays a crucial role in angiogenesis, the process of new blood vessel formation. In cancer, VEGFR2 is often overexpressed, promoting the growth of new blood vessels that supply the tumor with oxygen and nutrients, facilitating its growth and metastasis.
Inhibiting VEGFR2 signaling has been shown to be an effective strategy in cancer therapy, and several VEGFR2 inhibitors have been approved for the treatment of various types of cancer, including renal cell carcinoma, colorectal cancer, and non-small cell lung cancer. These inhibitors work by blocking the binding of VEGF to VEGFR2, thereby inhibiting angiogenesis and tumor growth.
Scientific Papers found: Click to Expand⟱
6442- SAO,    Medicinal properties of alpha-santalol, a naturally occurring constituent of sandalwood oil: review
- Review, RCC, NA
AntiTum↑, Apoptosis↑, TumCCA↑, *Inflam↓, selectivity↑, tumCV↓, Casp8↓, Casp9↓, Casp6↓, Casp3↓, cl‑PARP↑, angioG↓, VEGFR2↓, Akt↑, mTOR↓, TumCG↓, *GSTs↑, *antiOx↑, *ROS↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Akt↑, 1,   Apoptosis↑, 1,   Casp3↓, 1,   Casp6↓, 1,   Casp8↓, 1,   Casp9↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 1,   TumCG↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGFR2↓, 1,  

Drug Metabolism & Resistance ⓘ

selectivity↑, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 15

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSTs↑, 1,   ROS↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  
Total Targets: 4

Scientific Paper Hit Count for: VEGFR2, Vascular Endothelial Growth Factor Receptor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:407  Target#:768  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page